All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
KRAS is the most frequently mutated oncogene in solid tumors in general, and in lung tumors in particular. There are more patients whose lung tumors are driven by KRAS mutations than by ALK, Ros, Ret and TRK alterations. Combined. And after 40 years, they look to be getting a targeted therapy, or even two.
A Singapore study led by the Novartis Institute for Tropical Diseases (NITD) has shown that a novel small-molecule inhibitor of the dengue virus (DENV) nonstructural protein 4B (NS4B) has favorable pharmacokinetics and efficacy in preclinical animal models, the authors reported in the February 3, 2021, edition of ScienceTranslationalMedicine.
Keeping you up to date on recent developments in orthopedics, including: Blood pressure can be controlled without drugs after spinal cord injury; Researchers develop technique to replicate bone-remodeling processes; New technique to fast-track pain research.
Spatially resolved transcriptomics, which Nature Methods named as its Method of the Year for 2020, allows researchers to look at transcriptional activity while preserving the spatial relationship of different transcripts.
KRAS is the most frequently mutated oncogene in solid tumors in general, and in lung tumors in particular. There are more patients whose lung tumors are driven by KRAS mutations than by ALK, Ros, Ret and TRK alterations. Combined.
Keeping you up to date on recent developments in oncology, including: New nanotech approach to skin cancer in development at Yale; Imaging for prediction of response to hormone therapy; Algorithm is predictive of response to immunotherapy.
By combining synthetic biology and RNA therapy, the team at startup Strand Therapeutics Inc. hopes to make mRNA therapy more effective. Strand recently announced an immuno-oncology deal with Beigene Ltd. that netted the company $5 million to begin with and could end up being worth more than $250 million. Beyond immuno-oncology, the company’s basic technology could be broadly useful for both mRNA- and cell-based therapies.
Keeping you up to date on recent developments in cardiology, including: Registry data suggest invasive procedures may be omitted in some cardiac arrest patients; Cryoablation beats medical management for some AF patients; Aetna deems certain leadless pacing experimental.
RSS
